MedPath

Efficacy of Tryushanadi vati in Madhumeha

Not yet recruiting
Conditions
Type 2 diabetes mellitus without complications,
Registration Number
CTRI/2021/09/036449
Lead Sponsor
Priyanka Shivajirao Ambhure
Brief Summary

I am Priyanka Shivajirao Ambhure PG Scholar Kaya-Chikitsa trying to evaluate efficacy of Tryushnadi Vati in the management of Madhumeha.

During this trial trying to evaluate the untoward effect of Tryushnadi Vati in Madhumeha as there is no previous work done on Tryushnadi Vati

So emphasis will be made to find out easy, cost effective method to control Hyperglycemia with no side effects .

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
80
Inclusion Criteria
    1. Willing to give consent to participate in the study. 2. Age group limit.
  • 18 to 70 Years. 3 Irrespective of Sex, religion, education socio-economic & Marital Status. 4. Patient having Diabetes Mellitus Type 2 Fasting Blood Sugar range – 126 to 200mg/dl, Post Prandial Blood Sugar range – 200 to 300mg/dl. 5.Patient having Lakshnas of Madhumeha.
Exclusion Criteria
  • Patients of IDDM (Insulin Dependent Diabetes Mellitus)(DM Type 1).
  • 2.Patient with any major complication of Diabetes Mellitus Type2.
  • 3.Patient with Gestational Diabetes and those in Lactation.
  • Patient having any other major illness.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To determine efficacy of Tryushnadi Vati in Madhumeha4 Weeks
Secondary Outcome Measures
NameTimeMethod
To review literature on Madhumeha4 weeks

Trial Locations

Locations (1)

Hon Shri Annasaheb Dange Ayurved Medical College Ashta

🇮🇳

Sangli, MAHARASHTRA, India

Hon Shri Annasaheb Dange Ayurved Medical College Ashta
🇮🇳Sangli, MAHARASHTRA, India
Vd Priyanka Shivajirao Ambhure
Principal investigator
9923811679
priyankaambhure2106@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.